Qiming Venture Partners, established in 2006, is a leading China-based venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, and Singapore. It manages multiple funds totaling $9.5 billion, focusing on early and growth-stage investments in the Technology and Consumer (T&C) and Healthcare industries. With a strong track record, over 200 portfolio companies have achieved exits, and over 70 have become unicorns or super unicorns. Qiming Venture Partners USA, founded in 2017, is its affiliate in Cambridge, Massachusetts, specializing in healthcare, therapeutics, and digital health investments. The firm is known for its deep technical expertise, hands-on operational support, and thought leadership in the venture capital industry.
Room3906 Jinmao Tower, 88 Century Boulevard, Shanghai 200121, China
Zhang Ao
Executive Director
Artavazd Arumov Ph.D
Principal
Cyrus Chan
Associate
Nan Chen
Principal
David Chu
Partner
Phil DiGiacomo
Principal
Anna French
Managing Partner
Yuxin Fu
Vice President
Jinda Gao
Principal
Kuantai Yeh
Partner
Robert Headley
Partner
Maykin Ho
Venture Partner
William Hu
Managing Partner
Duane Kuang
Co-Founder and Managing Partner
Nisa Leung
Managing Partner
Dingzheng Li
Vice President
Jing Liu
Vice President
Chang Liu
Associate
Bin Liu
Vice President
Biao Lu
Associate
Shuo Mao
Principal
Will McConnell
Principal
Gary Rieschel
Founder and Managing Partner
James Shen
Venture Partner
Motao Sun
Vice President
Amy Tang
Venture Partner
Yi Tang
Principal
Shiyu Wang
Partner
Rachel Wang
Venture Partner
James Wang
Venture Partner
Jing Wu
Partner
Gillian Xu
RMB funds CFO
Peter (Ming) Yin
Principal, Cleantech
Janet Yu
Partner
Oscar Zhang
Principal
Yafeng Zhou
Associate
Alex Zhou
Partner
Zhiyuan Zhou
Associate
Zhifeng Zhou
Managing Partner
Jing-Shan Hu Ph.D
Venture Partner of Healthcare
Phillip DiGiacomo Ph.D
Principal
Past deals in Series C
Singular Medical
Series C in 2025
Singular Medical is a technology company focused on the research, development, and industrialization of cardiac rhythm management (CRM) products. The company designs and develops a comprehensive range of high-quality medical devices, including implantable cardioverter defibrillators, pacemakers, and implantable cardiac monitors. Singular Medical aims to provide reliable and professional medical equipment that addresses the needs of a large population of cardiac patients, offering solutions that span from initial detection to ongoing follow-up care.
Pulnovo Medical
Series C in 2025
Pulnovo Medical, founded in 2013 in Wuxi, Anhui, specializes in the development, production, and service of innovative medical devices aimed at treating pulmonary hypertension. The company focuses on advanced pulse radiofrequency ablation technology, which includes pioneering high-frequency ablation equipment and intravascular catheters. These products are designed to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure, offering a novel approach to treatment with a commitment to improving patient outcomes. Pulnovo Medical holds global invention patents for its unique technologies, underscoring its role as a leader in this specialized medical field.
Vivatides Therapeutics
Series C in 2025
Vivatides Therapeutics develops new RNA treatments to help improve patients' lives using biotechnology research.
Umoja Biopharma
Series C in 2025
Umoja Biopharma specializes in innovative immunotherapy aimed at transforming cancer treatment and enhancing patient quality of life. The company focuses on reprogramming T cells within the patient's body to effectively target cancer, including solid tumors and hematological cancers that often have poor responses to conventional therapies. Its proprietary CAR T-cell gene therapy platform is designed to deliver scalable therapeutic regimens tailored to various stages of cancer, enabling medical practitioners to directly and safely attack cancer cells. By harnessing the body's immune response, Umoja Biopharma seeks to improve overall patient outcomes and provide more effective treatment options for those affected by cancer.
Cornerstone Robotics
Series C in 2025
Cornerstone Robotics is dedicated to enhancing the accessibility of advanced medical services in China through the development of medical robotic devices. The company is focused on creating a safe and efficient surgical robotics platform aimed at improving the accuracy and efficiency of surgical operations. By prioritizing research and development, Cornerstone Robotics enables physicians to perform surgeries with greater precision, ultimately contributing to better patient outcomes in the healthcare sector.
Bioheng
Series C in 2024
BioHeng is a clinical biopharmaceutical and biotechnology Company focuses on novel immunotherapy and next-generation gene therapy development for treating cancers and various diseases. Founded in 2017, Bioheng has established a high standard GMP grade clinical translational center, and is leading in the field of cell engineering, proliferation and clinical applications. Particularly, Bioheng owns several cutting-edge patents plus extensive industry experience, and has built a complete, closed and automated production system in compliance with regulatory guidelines. In 2018, Bioheng has successfully raised tens of millions of RMB seeding fund from Simcere Pharmaceutical Group, aiming to accelerate the development of immunotherapy via integrating resources from both parties. Bioheng is dedicated to develop safer, effective and less expensive cell therapy drugs to benefit more patients.
iMile
Series C in 2024
iMile is a logistics and courier services provider operating across the Middle East, specializing in solutions for the e-commerce sector. The company is notable for being the first courier service to effectively address Cash On Delivery (COD) needs, offering a suite of services that includes cash-on-delivery options with tracking, real-time online shipment tracking, and comprehensive customer support available through various channels. iMile also facilitates international transport and maintains overseas warehouses, ensuring efficient last-mile delivery. Its innovative platform enables clients to manage cross-border deliveries seamlessly, enhancing the overall logistics experience.
Duet
Series C in 2024
Duet is a dating application helps you find meaningful relationships based on shared interests and experiences.
LaNova Medicines
Series C in 2024
LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.
Original Point
Series C in 2024
Original Point focuses on the development of CNC systems with five-axis and multi-axis linkage capabilities.
TandemAI
Series C in 2024
TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven, high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution.
LaNova Medicines
Series C in 2024
LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.
Dezhen Technology
Series C in 2024
Dezhen Technology provides solutions for medical institutions to help hospitals develop clinical, and scientific research management. Dezhen Technology is headquartered in Hongkou, China.
Yidao Biotechnology
Series C in 2024
Yidao Biotechnology research and develops vaccines and biomedical products. It focuses on the research and development of a variety of vaccines such as recombinant protein antigen vaccine, new virus vector vaccine, messenger RNA vaccine, and vaccine adjuvant platforms, providing vaccines to meet the needs of human health in both domestic and international markets. The Suzhou, Jiangsu-based biotech company was established in 2017.
Alamar Biosciences
Series C in 2024
Alamar Biosciences, founded in 2018 and based in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that enhances protein analysis and the diagnosis of various diseases through innovative antibody technologies. By facilitating the discovery of new biomarkers, Alamar aims to empower healthcare providers to identify diseases at an early stage, thereby improving potential treatment outcomes and patient care.
DH-Robotics
Series C in 2024
DH Robotics Technology Co., Ltd., founded in 2016 and based in China, specializes in the research and development of robotic hands and industrial robots. The company focuses on creating electric gripping jaws intended to enhance intelligent manufacturing processes. Its products are designed to be stable, secure, and easily integrated, catering to the needs of advanced manufacturing and lean production. By developing cost-effective solutions, DH Robotics aims to support flexible and intelligent demands within the manufacturing sector.
Leapstack
Series C in 2023
Leapstack is an insurance technology company based in Shanghai, with additional offices in Beijing and Nanjing. Founded in February 2016, it focuses on developing big data artificial intelligence solutions tailored for commercial insurance companies and social security management agencies. The company's platform enhances the insurance claims process by offering services such as risk control monitoring, post-medical reimbursement, anti-fraud measures, and compliance identification. By addressing inefficiencies in the industry, Leapstack aims to improve operational effectiveness and provide comprehensive data analysis and management tools for its clients.
SinoUnited Health
Series C in 2023
SinoUnited Health is a medical center based in Shanghai, China, specializing in sports medicine, physical therapy, pain management, orthopaedics, and neurology services. Established in 2004, the center offers a comprehensive range of treatments, including services for foot and ankle issues, acupuncture, chronic pain management, movement disorders, migraines, tremors, electromyography, balance training, and post-stroke care. The facility is designed to provide a comfortable environment that meets international standards, ensuring a high-quality experience for patients. SinoUnited Health has built a strong reputation for delivering reliable diagnoses and effective treatment outcomes, reinforcing its commitment to enhancing patient satisfaction and well-being within the community.
Prismlab China
Series C in 2022
Prismlab China Ltd. is a high-tech enterprise established in 2005, specializing in the development, production, and sales of high-speed light-curing 3D printers. The company integrates optical, mechanical, electrical technology, and computer software and hardware, along with photopolymer materials, to produce advanced rapid prototyping machines based on SLA technology. With a global presence, its products are distributed across over 50 countries and regions, earning recognition and acclaim from users worldwide for their performance and innovation.
Fushoukang
Series C in 2022
Shanghai Fushoukang Rehabilitative Home Nursing Services specializes in in-home rehabilitation and nursing care for the elderly, as well as individuals who are weak, sick, or disabled. Founded in 2011 and headquartered in Shanghai, the company offers a range of services including home care, community care, nursing care, and bathing assistance. By focusing on the needs of vulnerable populations, Fushoukang aims to enhance the quality of life for its clients through personalized care in the comfort of their own homes.
Tasogare
Series C in 2022
Tasogare Coffee is a premium coffee brand based in Japan that specializes in producing and supplying a diverse range of coffee products. The company operates through both online and retail channels, catering to a wide customer base that values high-quality coffee. Tasogare Coffee is committed to delivering exceptional coffee experiences, emphasizing quality in its offerings.
Belief Biomed
Series C in 2022
Belief Biomed brings the latest research achievements in precision medicine in Triangle area into production and promotes international collaboration by connecting established investors from China to explore the vast opportunity of North Carolina.
Eigencomm
Series C in 2022
EigenCOMM Ltd. is a Shanghai-based company established in 2017, specializing in the research, development, and sales of cellular network internet chips. The firm focuses on providing complete solutions for Internet of Things (IoT) ecosystems, particularly in the realm of smart home appliances. EigenCOMM's product line includes standard NB-IoT terminal chips, which ensure comprehensive coverage of cellular data connections and extended standby times, positioning the company as a key player in the IoT market.
Zhenge Biotech
Series C in 2022
Shanghai ZhenGe Biotechnology Co., Ltd. is a research and development company that specializes in the creation of drugs and protein therapeutics. Founded in 2017 and based in Shanghai, China, the company focuses on various aspects of drug development, including mammalian cell line development, upstream and downstream processing, and formulation development. Zhenge Biotech also offers contract development and manufacturing services, as well as assistance with regulatory filings such as IND and BLA. Additionally, the company provides a research platform for antibody development, transient infection processes, N-Glycosylation, and CAR-T technologies. Through these services, Zhenge Biotech supports the pharmaceutical industry in advancing innovative therapeutic solutions.
Yesmro
Series C in 2022
Yesmro, also known as Yimai Gongpin, is a retail company focused on supplying automation parts and industrial supplies to small and medium-sized enterprises. The company offers an extensive range of products, including electrical accessories, wires and cables, and industrial control components, catering specifically to the needs of businesses involved in technological development. By leveraging technology and data-driven approaches, Yesmro aims to deliver affordable and convenient solutions, enabling small enterprises to easily access the industrial products they require for their operations. The company's commitment to providing long-tail services ensures that even niche market needs are met efficiently and cost-effectively.
Rox Motor
Series C in 2021
ROX Motor is a company dedicated to the development of off-road new energy vehicles, focusing on innovations in smart car technologies. The firm specializes in research and development in areas such as new energy power, intelligent cockpit systems, and autonomous driving. By providing advanced solutions in three-electric technology and intelligent driving, ROX Motor aims to enhance product quality within the new energy vehicle industry. The company's commitment to integrating cutting-edge technologies supports its mission to lead in the smart vehicle market.
Abogen Biosciences
Series C in 2021
Abogen Biosciences, established in 2019 and headquartered in Jiangsu, China, specializes in the development of nucleic acid-based therapeutics, including RNA and DNA treatments, for combating cancer and infectious diseases.
Liangyihui
Series C in 2021
Suzhou Liangyihui Network Technology Co., Ltd. operates an authoritative online education and information platform focused on oncology. Based in Shanghai, China, the company collaborates with numerous reputable hospitals and institutions, both domestically and internationally, to address the information asymmetry in the cancer field. Liangyihui provides a comprehensive range of educational materials related to tumor treatment, including medical cases, conference information, online courses, and research reports. This platform serves as a valuable resource for oncologists and aims to enhance public understanding of cancer, promoting scientific knowledge and supporting efforts to prevent and combat the disease.
WeRide
Series C in 2021
WeRide is a leading, commercial-stage global company that develops Level 4 autonomous driving technologies. WeRide aims to develop safe and reliable driverless solutions to make mobility and transportation safer, more affordable and accessible. WeRide is conducting autonomous driving R&D, tests and operations in over 25 cities around the world. As the pioneer leader in autonomous technologies and services, WeRide has stepped up to the commercial stage in operations. WeRide offers an all-rounded product mix of Robotaxi, Robobus, Robovan, Robosweeper and ADAS, providing smart services in online ride-hailing, on-demand transport, urban logistics, sanitation services and acting as a solution provider. Established in 2017, WeRide is headquartered in Guangzhou, China, and has expanded its R&D and operation centers to Beijing, Shanghai, Shenzhen, Zhengzhou, Nanjing, Wuhan, and Anqing, as well as San Francisco in the US. WeRide has formed strategic partnerships with leading global OEMs and Tier 1 supplier including Renault-Nissan-Mitsubishi Alliance, Yutong Group, GAC Group, Bosch, etc.
Insilico Medicine
Series C in 2021
Insilico Medicine, Inc. is a biotechnology company that utilizes artificial intelligence to advance drug discovery, biomarker development, and research into aging. Founded in 2014 and based in Baltimore, Maryland, the company has developed a comprehensive AI platform that employs techniques such as generative adversarial networks and reinforcement learning to create novel molecular structures aimed at treating cancer and age-related diseases. Insilico Medicine operates various projects, including Pharma.AI, which offers machine learning services to biotechnology and pharmaceutical companies, and Young.AI, which predicts biological age. The company is actively engaged in internal drug discovery efforts targeting conditions like Alzheimer's disease, Parkinson's disease, and diabetes, and has partnered with Life Extension to produce nutraceutical products using advanced bioinformatics. Additionally, Insilico Medicine provides consumer applications and services to academic institutions and the cosmetic industry, solidifying its role in the intersection of AI and healthcare.
BrainHealth
Series C in 2021
BrainHealth focuses on the research and development, production, and sales of neurological medical equipment.
Yidao Biotechnology
Series C in 2021
Yidao Biotechnology research and develops vaccines and biomedical products. It focuses on the research and development of a variety of vaccines such as recombinant protein antigen vaccine, new virus vector vaccine, messenger RNA vaccine, and vaccine adjuvant platforms, providing vaccines to meet the needs of human health in both domestic and international markets. The Suzhou, Jiangsu-based biotech company was established in 2017.
Tungee
Series C in 2021
Tungee, established in 2016, is a provider of intelligent sales solutions for business-to-business enterprises. By utilizing big data and artificial intelligence technologies, including natural language processing and machine learning, Tungee offers a comprehensive platform that facilitates lead mining, business opportunity engagement, customer relationship management, and order analysis. This platform is designed to help enterprises efficiently identify, contact, and manage customers, thereby reducing customer acquisition costs and enhancing overall sales performance. Tungee has positioned itself as a leader in the Chinese intelligent sales sector, serving over 3,000 enterprise clients, including notable companies such as Alibaba and China Mobile. Through its innovative approach, Tungee addresses the challenges faced by businesses in sales forecasting and customer management.
P&R Measurement Technology
Series C in 2021
P&R Measurement Technology Co., Ltd., founded in 2011 and headquartered in Zhuhai, China, specializes in the research, development, and supply of testing and automation solutions. The company caters to various industries, including motors, household appliances, consumer electronics, and energy power. With a strong emphasis on engineering signal processing and acoustic/vibration testing, P&R Measurement offers a range of custom and semi-custom engineering testing equipment, as well as data processing and finite element simulation analysis services. The company operates subsidiaries in Guangzhou, Suzhou, Hong Kong, and the United States, with additional offices in Qingdao, Hefei, Shunde, and Ningde, enhancing its capacity to serve a diverse clientele.
SinoUnited Health
Series C in 2021
SinoUnited Health is a medical center based in Shanghai, China, specializing in sports medicine, physical therapy, pain management, orthopaedics, and neurology services. Established in 2004, the center offers a comprehensive range of treatments, including services for foot and ankle issues, acupuncture, chronic pain management, movement disorders, migraines, tremors, electromyography, balance training, and post-stroke care. The facility is designed to provide a comfortable environment that meets international standards, ensuring a high-quality experience for patients. SinoUnited Health has built a strong reputation for delivering reliable diagnoses and effective treatment outcomes, reinforcing its commitment to enhancing patient satisfaction and well-being within the community.
CastBox
Series C in 2021
CastBox is a spoken audio platform founded in 2016 and based in Beijing, China, with additional offices in Hong Kong and San Francisco. The platform allows users to easily find, access, and enjoy a wide range of spoken audio content, including podcasts, on-demand radio, and audiobooks, across multiple devices such as mobile phones, desktops, and smart home devices. CastBox employs proprietary technology, including curated podcast recommendations and an in-audio deep search feature powered by natural language processing and machine learning. This technology enables the platform to deliver personalized listening experiences tailored to individual user preferences and habits. The service is available in multiple languages, making it accessible to a global audience.
Matrixport
Series C in 2021
Matrixport is a comprehensive financial services platform focused on digital assets, allowing users to invest, trade, and leverage cryptocurrencies. The company provides a blockchain-based trading platform that facilitates the trading, custody, lending, and management of crypto assets. By offering a range of services, Matrixport empowers both individual users and institutional clients to effectively manage their financial resources and navigate the digital currency landscape.
Booming Technologies
Series C in 2021
Booming Tech is a cloud-based platform that specializes in game development and virtual reality. It provides tools for creators to design and innovate within virtual environments, catering to various applications, including gaming, industrial simulations, and other immersive experiences. The platform features a robust server architecture that ensures players can engage in real-time, stable interactions regardless of their geographical locations. By focusing on both entertainment and practical applications, Booming Tech supports a diverse range of virtual world creation, enabling users to explore new possibilities in digital interaction.
Fucunbao
Series C in 2021
Fucunbao is an application that provides medical management solutions specifically designed for rural communities in China. It operates an online insurance and medical portal that enables users to pay for insurance online, create reimbursement plans, and identify disease types. The platform aims to enhance access to insurance and medical services for underserved populations. By leveraging government funding and resources, Fucunbao helps subsidize insurance and medical expenses, addressing the financial burdens that often result from healthcare challenges in these areas.
Newsoara
Venture Round in 2021
Newsoara is a biomedical technology developer that specializes in the development of medical devices.
Yuanbao Tech
Series C in 2021
Yuanbao Tech is a technology company specializing in quantitative risk management for network security. It offers comprehensive services to enterprises, including risk quantitative assessment and analysis, continuous monitoring, and early warning management. Utilizing its self-developed platform, Yuanbao Tech provides integrated solutions that help clients evaluate and manage network security risks effectively, ultimately reducing the likelihood of cyber security incidents. The company's focus on innovative risk management tools positions it as a key player in enhancing organizational security strategies.
Liangyihui
Series C in 2021
Suzhou Liangyihui Network Technology Co., Ltd. operates an authoritative online education and information platform focused on oncology. Based in Shanghai, China, the company collaborates with numerous reputable hospitals and institutions, both domestically and internationally, to address the information asymmetry in the cancer field. Liangyihui provides a comprehensive range of educational materials related to tumor treatment, including medical cases, conference information, online courses, and research reports. This platform serves as a valuable resource for oncologists and aims to enhance public understanding of cancer, promoting scientific knowledge and supporting efforts to prevent and combat the disease.
Yunji Technology
Series C in 2021
Yunji Technology is a Chinese company that specializes in the development of commercial service robots designed to improve efficiency and reduce costs in customer service operations. Its robots are aimed at enhancing service experiences across various sectors, including hospitality, luxury retail, and restaurants. By automating certain aspects of customer service, Yunji Technology's solutions enable clients to save time and streamline their operations, ultimately empowering businesses to deliver improved services to their customers.
Insight Lifetech
Series C in 2020
Insight Lifetech is a medical technology company focused on creating innovative solutions for the diagnosis and treatment of cardiovascular diseases. It has developed a synergistic platform that integrates research and development, manufacturing, and commercialization, which enhances collaboration, accelerates product development, and promotes cost efficiency. The company is notable for creating the first and only domestic fractional flow reserve (FFR) system in China that has received approval from the National Medical Products Administration (NMPA). By manufacturing high-quality medical devices that feature reliable precision diagnostics and therapeutic capabilities, Insight Lifetech aims to empower physicians to improve patient outcomes and save lives.
dMed
Series C in 2020
dMed is a full-service Clinical Contract Research Organization that provides industry solutions to pharma and medical device companies. Its business covers consulting, regulatory affairs & strategy, early clinical development, clinical science & medical affairs, clinical operations, biostatistics & programming, data management, drug safety & pharmacovigilance, quality assurance, and information solutions. dMed has set up offices in major cities, including Shanghai, Beijing, Wuhan, New York, Washington, San Francisco, and Brussels, and it employs around 600 professionals globally, among them 60% holds master above degree and 25% with more than 10 years working experiences.
Nice Tuan
Series C in 2020
Nice Tuan is an e-commerce platform specializing in fresh produce, beverages, leisure food, and a variety of daily supplies. The company operates a community-focused model, partnering with local residential communities to source products from nearby warehouses and producers. By doing so, Nice Tuan aims to provide comprehensive grocery and household item offerings tailored to the needs of local residents. The platform emphasizes efficiency and convenience, striving to create a well-integrated community e-commerce ecosystem centered on daily groceries and fresh produce.
ZEGOCLOUD
Venture Round in 2020
Shenzhen Zego Technology Co., Ltd. is a company based in Shenzhen, China, that specializes in real-time cloud streaming services for audio and video communications. Founded in 2015, Zego offers a comprehensive platform that supports various functionalities, including one-to-one video calls, live broadcasting, and multi-party video conferencing. The platform also provides services for real-time audio streaming, voice chatrooms, and recording and archiving of events such as bank account openings and interviews. Zego targets enterprise and mobile application developers, focusing on delivering stable and high-quality voice and video services across diverse sectors, including social media, online education, and telemedicine. Additionally, the company provides a software development kit (SDK) to facilitate the integration of its services into other applications.
Broncus Medical
Series C in 2020
Broncus Medical is a medical technology company specializing in the development of minimally-invasive devices for treating lung diseases, including emphysema and lung cancer. Based in Mountain View, California, with an international presence in Nyon, Switzerland, Broncus is focused on addressing significant unmet medical needs in interventional pulmonology. The company is exploring its Exhale product line, which features a patented treatment method known as Airway Bypass, aimed at providing a minimally-invasive solution for patients suffering from homogeneous emphysema. Broncus is currently conducting the pivotal EASE Trial, enrolling patients worldwide to evaluate the efficacy of this treatment in severe cases of the disease. Additionally, Broncus offers a range of innovative products designed to enhance diagnostic and therapeutic outcomes in lung care, including the Archimedes System, LungPoint, and InterVapor System.
Petkit
Series C in 2020
Shanghai PETKIT Network Technology Co., Ltd., founded in 2013, specializes in developing and manufacturing innovative pet care products. Based in Shanghai, China, the company offers a diverse range of smart devices designed to enhance the health and well-being of pets. Its product lineup includes smart feeders, antibacterial bowls, drinking fountains, and pet monitoring devices that track activity levels, calorie consumption, and overall health. Additionally, Petkit provides a mobile application that integrates with its smart devices, allowing pet owners to monitor their pets' behaviors and health metrics conveniently. By combining technology with pet care, Petkit aims to simplify pet management for owners while ensuring the welfare of their animals.
Antengene
Series C in 2020
Antengene Corporation is a biopharmaceutical company based in Shanghai, China, founded in 2016, that specializes in the development of innovative therapies for cancer treatment. The company's portfolio includes ATG-010 (selinexor), targeting hematologic malignancies such as multiple myeloma, and ATG-008 (onatasertib), an mTOR kinase inhibitor aimed at treating advanced solid tumors and hematological malignancies. Antengene's pipeline features several investigational products, including ATG-016 (eltanexor), ATG-527 (verdinexor), and ATG-019, along with pre-clinical candidates like ATG-101, a bi-specific antibody, and ATG-012, a KRAS G12C inhibitor. The company is committed to addressing unmet medical needs in Asia through its focus on the discovery, development, and commercialization of first-in-class therapeutics for various types of cancer.
Nice Tuan
Series C in 2020
Nice Tuan is an e-commerce platform specializing in fresh produce, beverages, leisure food, and a variety of daily supplies. The company operates a community-focused model, partnering with local residential communities to source products from nearby warehouses and producers. By doing so, Nice Tuan aims to provide comprehensive grocery and household item offerings tailored to the needs of local residents. The platform emphasizes efficiency and convenience, striving to create a well-integrated community e-commerce ecosystem centered on daily groceries and fresh produce.
LetsGetChecked
Series C in 2020
LetsGetChecked is a healthcare technology company that facilitates at-home health testing. It connects users with regulated laboratories worldwide for various tests, including general wellness, sexual health, women's health, men's health, and COVID-19. Users collect samples at home using provided kits and mail them back for analysis; results are then accessible online. The platform aims to empower individuals to proactively manage their health, offering services across the United States, Canada, and Europe.
Pratilipi
Series C in 2020
Pratilipi is a storytelling platform that connects readers and writers in multiple Indian languages. It provides a space for authors to share their stories, poems, and books, allowing millions of users to discover, read, and engage with content in their preferred language and format. By facilitating the sharing of narratives, Pratilipi fosters a vibrant community where users can express themselves and enjoy diverse stories online. The platform caters to a wide audience, making literature accessible and enjoyable for individuals across different backgrounds and preferences.
Viewtrix Technology
Series C in 2020
Viewtrix Technology specializes in the development of display driver chips and circuit boards, focusing on enhancing display resolution and color representation. The company's technologies support a variety of display types, including LCD, LED, and OLED, making them applicable to mobile phones, tablets, and notebooks. By providing these advanced solutions, Viewtrix Technology enables electronics manufacturers to improve the display quality of their products while also reducing costs.
Yunyinggu
Series C in 2020
Yunyinggu Technology Co., Ltd. is a Chinese start-up focused on the development and promotion of innovative display technologies aimed at enhancing the performance of flat panel displays. The company has created a proprietary solution recognized for achieving superior pixel density, or high pixels per inch (PPI), which can be utilized across various types of flat panels, including LCD, LED, and OLED displays. By advancing display technology, Yunyinggu seeks to contribute to the evolving landscape of visual performance in consumer electronics.
DiNovA Medtech
Series C in 2020
DiNovA Medtech develops vascular intervention technology for the treatment of aneurysm. Weiqiang Medical Technology specializes in researching and developing innovative vascular dilation products including aortic stent graft system, intraoperative stent system, peripheral vascular stent, and other supporting medical devices, aiming to provide advanced, effective medical solutions for the complicated treatments of various aortic vascular diseases.
Shulan Health
Series C in 2020
Shulan Health operates a hospital center focused on enhancing patient well-being through a range of healthcare services. These services include rehabilitation, nutrition, health examinations, and remote consultations, all designed to meet the diverse needs of patients. The facility adheres to accredited international medical standards, ensuring high-quality care. By integrating advanced IT technology, Shulan Health aims to deliver a personalized and holistic healthcare experience, contributing significantly to the overall health outcomes of its patients.
Abbisko Therapeutics
Series C in 2020
Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering, developing, and manufacturing innovative immuno-oncology therapies. Founded in 2016 by a team with extensive experience in drug research and management, the company specializes in small molecule therapies for various conditions, including cancer, metabolic diseases, liver diseases, viral infections, and central nervous system disorders. Abbisko's notable products include ABSK011 and ABSK021, which are designed to treat hepatocellular carcinoma, as well as CSF1R, aimed at addressing solid tumors. The company is dedicated to advancing its pipeline of therapeutics to improve patient outcomes in oncology and beyond.
Element Science
Series C in 2020
Element Science, Inc. is a medical device and digital health company focused on developing solutions for high-risk cardiovascular patients. The company's flagship product is a patch-based wearable cardioverter defibrillator that continuously monitors heart activity to protect against sudden cardiac death. This device integrates advanced data science and machine learning algorithms with strict electromechanical medical device standards, creating a proprietary digital platform that enhances patient care as individuals transition from hospital to home. Founded in 2011 and headquartered in San Francisco, California, Element Science aims to address critical health needs and reduce hospitalization rates associated with heart disease. The company was previously known as Revive Defibrillation Systems, Inc. before adopting its current name in 2014.
IntoCare
Series C in 2020
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.
Jacobio Pharmaceuticals
Series C in 2020
Jacobio Pharmaceuticals, established in 2015 in Beijing, China, is a clinical-stage biotech company specializing in the discovery and development of innovative therapies, particularly in oncology. The company aims to address unmet medical needs both in China and globally, focusing on serious diseases such as cancer, autoimmune disorders, and infectious diseases. Founded by experienced executives with a strong track record in the pharmaceutical industry, Jacobio has rapidly built a skilled research and development team of over 100 employees. This team possesses comprehensive capabilities in target discovery, medicinal chemistry, pharmacology, and clinical registration. Jacobio has developed a robust pipeline of 8 to 10 drug candidates, with JAB-3068 being the most advanced program. This candidate targets novel pathways for both immunotherapy and targeted therapies and has entered Phase I clinical trials in the United States, with additional trials planned in China.
DST Car
Series C in 2020
DiShangTie Car Rental (Shenzhen) Co., Ltd. is a company based in Shenzhen, China, specializing in the rental and maintenance of commercial electric vehicles (EVs) for passenger and cargo transportation. Established in 2015, the company focuses on the transportation and logistics sector, providing sustainable energy vehicle rental services tailored for the new energy logistics market. DiShangTie also manufactures electric car charging stations, supporting its commitment to offering green and sustainable vehicle leasing alternatives to major express logistics and urban distribution companies. Through its services, the company aims to facilitate the adoption of environmentally friendly transport solutions in China.
KeChow Pharma
Series C in 2019
Shanghai Kechow Pharma, Inc. is a biopharmaceutical company established in 2014 and headquartered in Shanghai, China. The company specializes in the discovery of targeted small molecule drugs, aiming to develop innovative therapies that improve upon existing treatments. KeChow Pharma collaborates with various partners to co-develop its drug candidates, emphasizing a commitment to advancing healthcare through novel therapeutic solutions.
DiNovA Medtech
Series C in 2019
DiNovA Medtech develops vascular intervention technology for the treatment of aneurysm. Weiqiang Medical Technology specializes in researching and developing innovative vascular dilation products including aortic stent graft system, intraoperative stent system, peripheral vascular stent, and other supporting medical devices, aiming to provide advanced, effective medical solutions for the complicated treatments of various aortic vascular diseases.
SinoUnited Health
Series C in 2019
SinoUnited Health is a medical center based in Shanghai, China, specializing in sports medicine, physical therapy, pain management, orthopaedics, and neurology services. Established in 2004, the center offers a comprehensive range of treatments, including services for foot and ankle issues, acupuncture, chronic pain management, movement disorders, migraines, tremors, electromyography, balance training, and post-stroke care. The facility is designed to provide a comfortable environment that meets international standards, ensuring a high-quality experience for patients. SinoUnited Health has built a strong reputation for delivering reliable diagnoses and effective treatment outcomes, reinforcing its commitment to enhancing patient satisfaction and well-being within the community.
NEIWAI
Series C in 2019
NEIWAI is a mid-to-high-end underwear brand founded in Shanghai in 2012, dedicated to providing comfortable clothing that respects the feelings of women. The company emphasizes a design philosophy that harmonizes comfort, function, and beauty, resulting in a diverse range of products suitable for various daily activities, including home and sports. Over the past five years, NEIWAI has served more than 200,000 female customers, reflecting its commitment to meeting the needs of its clientele. By focusing on the comfort of close-fitting clothing, NEIWAI aims to enhance the everyday experiences of its customers through thoughtfully designed underwear.
Yunyinggu
Series C in 2019
Yunyinggu Technology Co., Ltd. is a Chinese start-up focused on the development and promotion of innovative display technologies aimed at enhancing the performance of flat panel displays. The company has created a proprietary solution recognized for achieving superior pixel density, or high pixels per inch (PPI), which can be utilized across various types of flat panels, including LCD, LED, and OLED displays. By advancing display technology, Yunyinggu seeks to contribute to the evolving landscape of visual performance in consumer electronics.
Amphivena Therapeutics
Series C in 2019
Amphivena Therapeutics is a clinical-stage immuno-oncology company focused on developing bifunctional antibody therapies aimed at treating hematologic malignancies. Founded in 2012 and based in South San Francisco, California, the company utilizes its proprietary ReSTORE platform to create dual-action biologics that enhance the patient's immune response against cancer. These therapies are designed to relieve immune suppression while activating T cells, thereby promoting the destruction of tumor cells and their precursors. The platform emphasizes avidity, target selectivity, and safety, and can be engineered to include additional functionalities for targeting solid tumors. As a subsidiary of Affimed N.V., Amphivena Therapeutics aims to provide innovative treatment options for patients facing blood cancers.
Tisenc
Series C in 2019
Shenzhen Tisenc Medical Devices Co., Ltd., established in 2015, is a Sino-foreign joint venture based in Shenzhen, Guangdong. The company specializes in the development, manufacturing, and global sales of chemiluminescence immunology (CLIA) systems, including advanced point-of-care testing (POCT) systems and molecular diagnostic solutions. Tisenc operates from a facility covering over 16,000 square meters, which houses research and development laboratories, a GMP-certified factory, and an instrument manufacturing facility. The company holds full intellectual property rights for its products and technologies, allowing for complete independence in research, development, and production. Tisenc's innovative technologies support medical practitioners by providing reliable diagnostic reagents and automatic chemiluminescent analyzers, contributing significantly to the field of medical diagnostics.
Hesai Technology
Series C in 2019
Hesai Technology is a company based in Shanghai, China, founded in 2014. It specializes in designing laser radar systems using smart sensing technology. The primary application of these systems is to facilitate autonomous driving by enabling car companies to monitor mixed gas composition and detect hazardous leaks. Additionally, Hesai Technology develops natural gas leak detection systems for industrial processes. Its LiDAR products are used in a variety of applications including advanced driver assistance systems (ADAS), autonomous vehicle fleets, last-mile delivery robots, street sweeping robots, and logistics robots. The company operates through two main segments: the LiDAR segment and the gas detection segment, with the former being the primary revenue generator.
Huimei Technology
Series C in 2019
Huimei Technology is a National high-tech enterprise that offers medical artificial intelligence solutions.
Webuy Group
Series C in 2019
Webuy Group, established in 2017 and headquartered in Hangzhou, China, operates as a community-based e-commerce platform focused on apparel. The company owns several brands, including Shaking Baby and Haoyiku. Webuy Group utilizes a social e-commerce model that connects consumers with brands through WeChat, China's leading social media application. This platform allows merchants to share product links directly within their social networks, facilitating immediate purchases. By leveraging trust built through these networks, Webuy Group enhances customer engagement and offers features such as quick payment settlements and low return rates. Additionally, the company provides ongoing training to support business improvement, helping partner brands manage inventory effectively while enabling individual merchants to reach their customers more efficiently.
Haoyiku
Series C in 2019
Haoyiku is a community-based e-commerce platform founded in 2017 by Qiangqiang Wu and based in Hangzhou. The company focuses on apparel and employs a unique S2b2C model, connecting suppliers, businesses, and consumers. By leveraging social networks and the WeChat app, Haoyiku facilitates a seamless shopping experience that includes rapid payment settlements and enhanced customer outreach. This model not only allows partner brands to efficiently off-load inventory but also enables individual merchants to sell products within their social circles, contributing to a low return rate and ongoing business improvement through training and support.
RedDoorz
Series C in 2019
RedDoorz is an online platform that facilitates the discovery and booking of budget accommodations across Southeast Asia. Founded in 2015 and headquartered in Singapore, the platform connects travelers with a network of standardized budget hotels and guesthouses, primarily offering two-star and three-star properties. RedDoorz provides hotel partners with tools to enhance their visibility, manage distribution, marketing, customer experience, and pricing, thereby improving their operational efficiency and revenue potential. The company employs over 1,000 people across five countries and has received backing from notable investors, including Jungle Ventures and the International Finance Corporation. With a focus on delivering reliable stays, RedDoorz ensures that travelers benefit from essential amenities such as free Wi-Fi, clean rooms, and comfortable beds.
Delta Medical
Series C in 2019
Beijing Delta Medical Co., Ltd. specializes in the design and manufacture of orthopedic surgical instruments and rehabilitation products. The company offers a range of products, including shoulder arthroscopic instruments, various types of suture anchors, instruments for anterior and posterior cruciate ligament reconstruction, interference screws, and shaver systems. In addition to its surgical instruments, Delta Medical provides sports rehabilitation services. The company is headquartered in Beijing, China, and focuses on delivering innovative solutions in sports medicine.
WorkTrans
Series C in 2019
WorkTrans is a human resource management software developer based in China that offers a comprehensive platform designed to enhance various HR functions. The company's software provides diversified attendance management, mobile scheduling, and unified oversight, facilitating efficient payroll processing, roster management, recruitment, and training. By streamlining these processes, WorkTrans aims to improve recruiting efficiency and expand development opportunities for its clients, allowing organizations to adapt to their evolving workforce needs.
New Horizon Health
Series C in 2019
New Horizon Health is a biotechnology company based in Hangzhou, China, with an additional office in Beijing, specializing in the development of innovative technologies for early cancer detection and screening. Founded in 2015, the company primarily focuses on gastrointestinal cancers, offering products such as the ColoClear and Pupu Tube, which utilize fecal gene analysis (FIT-DNA) technology for colorectal cancer screening. These products enable users to conduct in-home tests, allowing for the early detection of colon cancer and precancerous lesions that may not be identified through traditional blood tests. New Horizon Health aims to reduce cancer morbidity and mortality rates by promoting accessible and efficient health services, leveraging big data and artificial intelligence in its screening technologies. The company's commitment to early cancer screening reflects its mission to enhance public health by facilitating widespread access to vital diagnostic tools.
Hesai Technology
Series C in 2019
Hesai Technology is a company based in Shanghai, China, founded in 2014. It specializes in designing laser radar systems using smart sensing technology. The primary application of these systems is to facilitate autonomous driving by enabling car companies to monitor mixed gas composition and detect hazardous leaks. Additionally, Hesai Technology develops natural gas leak detection systems for industrial processes. Its LiDAR products are used in a variety of applications including advanced driver assistance systems (ADAS), autonomous vehicle fleets, last-mile delivery robots, street sweeping robots, and logistics robots. The company operates through two main segments: the LiDAR segment and the gas detection segment, with the former being the primary revenue generator.
zuzuche.com
Series C in 2019
ZuzuChe.com operates an online platform that facilitates car rental services both in China and internationally. Founded in 2011 and headquartered in Guangzhou, the company provides users with access to comprehensive car rental information, enabling searches for designated driving, car chartering, and special events across more than 200 cities in China. ZuzuChe offers a wide range of services, including overseas car rentals, local attractions, Chinese GPS, and international driver's license translation. Additionally, the platform provides various insurance options, such as car damage theft insurance and personal liability coverage. Users can also book tickets and hotels through the platform, which is accessible via a mobile application. By integrating advanced search technology and real-time pricing comparisons, ZuzuChe aims to create a convenient and user-friendly experience for travelers.
Insta360
Series C in 2019
Insta360 is a technology company founded in 2014 that specializes in the development of advanced camera systems designed to help individuals capture and share their experiences. Based in Shenzhen, the company has established itself as a leader in the 360-degree camera market, offering a range of products tailored for different needs, from professional-grade models like the 8K Insta360 Pro to versatile options such as the Insta360 ONE. These cameras allow users to take high-definition 360-degree photos and videos, as well as live-stream their experiences on popular social media platforms. Insta360 also produces lightweight, portable cameras and attachments for mobile devices, catering to various scenarios including vlogging and cinematic virtual reality. The company is committed to pushing the boundaries of performance and accessibility, enabling users to create immersive content that transports viewers into new experiences.
Zuiyou
Series C in 2019
Zuiyou is a social networking mobile application designed for users born in the 1990s, facilitating the sharing and discovery of content, including recommendations, topics, and videos. The platform distinguishes itself by decentralizing user comments, presenting them in a non-linear manner rather than prioritizing them based on popularity. This approach encourages diverse interactions and allows users to engage with content in a more organic and personalized way. Through its innovative features, Zuiyou aims to foster a unique community where individuals can connect over shared interests and explore a wide array of topics.
Petkit
Series C in 2019
Shanghai PETKIT Network Technology Co., Ltd., founded in 2013, specializes in developing and manufacturing innovative pet care products. Based in Shanghai, China, the company offers a diverse range of smart devices designed to enhance the health and well-being of pets. Its product lineup includes smart feeders, antibacterial bowls, drinking fountains, and pet monitoring devices that track activity levels, calorie consumption, and overall health. Additionally, Petkit provides a mobile application that integrates with its smart devices, allowing pet owners to monitor their pets' behaviors and health metrics conveniently. By combining technology with pet care, Petkit aims to simplify pet management for owners while ensuring the welfare of their animals.
MicroTech Medical
Series C in 2018
MicroTech Medical, established in January 2011 in Hangzhou Future Technical City, focuses on the research, development, manufacturing, and commercialization of diabetes management devices. The company aims to innovate and produce high-tech and affordable medical devices for diabetes care, including both treatment and monitoring solutions. With a significant portion of its revenue generated in China, MicroTech Medical is dedicated to enhancing diabetes management both domestically and globally. The company has received investment from Eli Lilly and Company, which underscores its commitment to advancing diabetes care technology.
APT Medical
Series C in 2018
APT Medical Inc. is a high-tech enterprise focused on the research, development, manufacture, and sale of minimally invasive interventional medical devices targeting cardiovascular and cerebrovascular diseases. The company offers a range of products, including electrophysiological catheter delivery systems, radiofrequency ablation and mapping catheters, as well as various vascular intervention products and accessories. APT Medical also provides OEM and ODM services for catheter and metal products. Founded in 2002 and headquartered in Shenzhen, China, the company operates production facilities in Guanlan, Shenzhen, and Xiangxiang, Hunan, and markets its products across Europe, Eastern Europe, Southeast Asia, and other regions worldwide.
Akulaku
Series C in 2018
Akulaku Inc. is a prominent banking and digital finance platform headquartered in Jakarta, Indonesia, founded in 2016. It operates across Southeast Asia, including Indonesia, the Philippines, and Malaysia, focusing on meeting the financial needs of underserved customers in emerging markets. The company provides a variety of services, including digital banking, financing, investment, and insurance brokerage. Its offerings feature a virtual credit card, an e-commerce platform, and Asetku, an online wealth management service. Additionally, Akulaku has launched Neobank, a mobile digital bank supported by Bank Neo Commerce. The company aims to serve 50 million users in Southeast Asia by 2025, facilitating a range of financial transactions, from mobile top-ups to installment shopping, thereby enhancing the shopping experience for its users.
ET Healthcare
Series C in 2018
ET Healthcare, Inc. is an in vitro diagnostics company that specializes in manufacturing central laboratory analyzers for both inpatient and outpatient testing in various hospital settings, including pediatric care, intensive care units, and emergency rooms. The company has developed the Pylon Immunochemistry System, which integrates laboratory analysis with point-of-care testing to meet diverse immunodiagnostic needs, such as inflammation, cardiac function, fertility, infectious diseases, and tumor detection. Additionally, the Pylon BNP Immunoassay supports heart failure management by measuring B-type natriuretic peptide levels in plasma. ET Healthcare's products aim to bring the performance of traditional central lab analyzers to near-patient settings, addressing requirements for space, plumbing, and staffing. Headquartered in Palo Alto, California, the company also has offices in Shanghai and manufacturing facilities in Suzhou, China.
SequoiaDB
Series C in 2018
SequoiaDB Corporation is a distributed database company based in Shenzhen, China, established in 2011. It offers a range of products, including SequoiaDB, an enterprise-class distributed relational database designed for online transactions, data centers, and content management applications, as well as SequoiaCM, a solution for managing unstructured data in large and medium-sized enterprises. The company provides services in online transaction processing, content management, and data lake solutions, primarily catering to financial institutions such as banks, insurance firms, and securities companies. SequoiaDB is committed to research and development, aiming to become a global leader in the database industry, and has been recognized in Gartner's reports for its innovative database systems.
Jacobio Pharmaceuticals
Series C in 2018
Jacobio Pharmaceuticals, established in 2015 in Beijing, China, is a clinical-stage biotech company specializing in the discovery and development of innovative therapies, particularly in oncology. The company aims to address unmet medical needs both in China and globally, focusing on serious diseases such as cancer, autoimmune disorders, and infectious diseases. Founded by experienced executives with a strong track record in the pharmaceutical industry, Jacobio has rapidly built a skilled research and development team of over 100 employees. This team possesses comprehensive capabilities in target discovery, medicinal chemistry, pharmacology, and clinical registration. Jacobio has developed a robust pipeline of 8 to 10 drug candidates, with JAB-3068 being the most advanced program. This candidate targets novel pathways for both immunotherapy and targeted therapies and has entered Phase I clinical trials in the United States, with additional trials planned in China.
CANbridge Pharmaceuticals
Series C in 2018
CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.
Zuiyou
Series C in 2018
Zuiyou is a social networking mobile application designed for users born in the 1990s, facilitating the sharing and discovery of content, including recommendations, topics, and videos. The platform distinguishes itself by decentralizing user comments, presenting them in a non-linear manner rather than prioritizing them based on popularity. This approach encourages diverse interactions and allows users to engage with content in a more organic and personalized way. Through its innovative features, Zuiyou aims to foster a unique community where individuals can connect over shared interests and explore a wide array of topics.
Moretickets
Series C in 2018
Moretickets is an online ticketing company based in Shanghai that operates a ticketing platform aimed at providing users with direct access to performance tickets. By employing a multi-channel ticket bidding mechanism, Moretickets eliminates intermediaries and offers strictly audited tickets at discounted prices. This approach allows users to obtain detailed performance information while purchasing tickets at lower costs. The company's focus on transparency and affordability distinguishes it in the competitive ticketing market.
Lanjinrong
Series C in 2018
Lanjinrong is a Beijing Based Fintech Start Up.
Bang Er Orthopedic
Series C in 2018
Zhejiang Bang Er Medical Investment Management Co., Ltd. is a prominent operator of hospitals specializing in orthopedic care and rehabilitation services, established in 2012 in Zhejiang Province, China. The company focuses on the diagnosis and treatment of various orthopedic conditions, including trauma-related injuries, hand and foot surgery, spine surgery, and joint surgery. By offering a comprehensive range of services, Bang Er aims to provide patients with the necessary care and treatment options for their orthopedic ailments, positioning itself as a key player in the healthcare sector of the Yangtze River Delta.
XSKY Data Technology
Series C in 2018
XSKY Data Technology, based in Beijing, specializes in software-defined infrastructure products and services. It offers a range of storage solutions, including XCBS (cloud), XEBS (block), XEUS (unified), XEOS (object), and XEDP (unified data platform), catering to diverse sectors such as finance, enterprise, telecom, energy, and government. XSKY is a significant contributor to the open-source Ceph storage system, ranking top 3 globally. It partners with leading tech companies like Intel and Samsung, providing scalable, cost-effective storage solutions tailored for enterprise data center innovation.
CMLabs
Series C in 2018
The Chain Medical Labs is a professional independent medical laboratory established from a team of experienced technical and management experts which is one of the Shanghai Chain medical investment management Inc. also alliance with few internationally renowned lab and vendors. The company utilize advanced testing methods, quality management systems, automation technology as Europe, America and Japan for their Clinical Diagnostics. CMLabs features in clinical laboratory services, clinical trial services, research services, and laboratory information system services to support all medical institutions, as well as assist to obtain ISO15189 certification, CAP accreditation (United States Association of pathology quality system), SOP process and external audit services.
Eceyes Internet Financial
Series C in 2018
Eceyes Internet Financial is an insurance technology platform offering insurance and related products.
Miaoshou Doctor
Series C in 2018
Miaoshou Doctor is a healthcare service platform established in 2015 by Tao He and Daoliang Han, headquartered in Beijing. The company focuses on facilitating communication between patients and healthcare professionals, enabling effective management of post-diagnosis outcomes. Its platform empowers doctors to actively monitor their patients' health through ongoing counseling and prescription support, enhancing the overall patient care experience. By streamlining interactions and follow-ups, Miaoshou Doctor aims to improve health outcomes and foster better relationships between patients and their healthcare providers.
Bondent
Series C in 2018
Bondent Technology Co., Ltd., headquartered in Shanghai, China, specializes in supplying dental equipment and materials. It offers a comprehensive range of services, including technical training, operational and management consulting, decoration design, and financial solutions. Bondent's core business involves the design, development, manufacturing, and sales of oral medical equipment, creating a full ecosystem for the dental and oral health industry.
XiaoMan Technology
Series C in 2018
Xiaoman Technology, established in 2013 and based in Shenzhen, China, specializes in providing foreign trade solutions that leverage big data and artificial intelligence. The company develops SaaS-based business management services that encompass customer relationship management, marketing, sales management, and other core business functions. Its offerings are designed to be flexible and compatible, catering to the standardization needs of small and micro enterprises while also addressing the customization requirements of larger organizations. By focusing on comprehensive customer-oriented research and development, as well as effective sales, marketing, and service strategies, Xiaoman Technology aims to enhance customer service, improve sales productivity, and help businesses expand their international operations.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.